CoChat

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults

Open access
Kesari, Santosh, Schiff, David, Doherty, Lisa, Gigas, Debra C., Batchelor, Tracy T., Muzikansky, Alona, O'Neill, Alison, Drappatz, Jan, Chen-Plotkin, Alice S., Ramakrishna, Naren, Weiss, Stephanie E., Levy, Brenda, Bradshaw, Joanna, Kracher, Jean, Laforme, Andrea, Black, Peter McL., Folkman, Judah, Kieran, Mark, Wen, Patrick Y. · 2007 · Neuro-Oncology
Cited by 122

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Preclinical evidence suggests that continuous low-dose daily (metronomic) chemotherapy may inhibit tumor endothelial cell proliferation (angiogenesis) and prevent tumor growth. This phase II study evaluated the feasibility of this antiangiogenic chemotherapy regimen in adults with recurrent malignant gliomas. The regimen consisted of low-dose etoposide (35 mg/m2 [maximum, 100 mg/day] daily for 21 days), alternating every 21 days with cyclophosphamide (2 mg/kg [maximum, 100 mg/day] daily for 21 days), in combination with daily thalidomide and celecoxib, in adult patients with recurrent malignant gliomas. Serum and urine samples were collected for measurement of angiogenic peptides. Forty-eight patients were enrolled (15 female, 33 male). Twenty-eight patients had glioblastoma multiforme (GBMs), and 20 had anaplastic gliomas (AGs). Median age was 53 years (range, 33-74 years), and median KPS was 70 (range, 60-100). Therapy was reasonably well tolerated in this heavily pretreated population. Two percent of patients had partial response, 9% had a minor response, 59% had stable disease, and 30% had progressive disease. For GBM patients, median progression-free survival (PFS) was 11 weeks, six-month PFS (6M-PFS) was 9%, and median overall survival (OS) was 21 weeks. For AG patients, median PFS was 14 weeks, 6M-PFS was 26%, and median OS was 41.5 weeks. In a limited subset of patients, serum and urine angiogenic peptides did not correlate with response or survival (p > 0.05). Although there were some responders, this four-drug, oral metronomic regimen did not significantly improve OS in this heavily pretreated group of patients who were generally not eligible for conventional protocols. While metronomic chemotherapy may not be useful in patients with advanced disease, further studies using metronomic chemotherapy combined with more potent antiangiogenic agents in patients with less advanced disease may be warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1215/15228517-2007-006

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 122

Metadata

Authors
Kesari, S., Schiff, D., Doherty, L., Gigas, D. C., Batchelor, T. T., Muzikansky, A., O'Neill, A., Drappatz, J., Chen-Plotkin, A. S., Ramakrishna, N., Weiss, S. E., Levy, B., Bradshaw, J., Kracher, J., Laforme, A., Black, P. M., Folkman, J., Kieran, M., & Wen, P. Y.
Venue
Neuro-Oncology
Published
2007-07-01
Volume
9
Issue
3
Pages
354-363
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2161637607
Cited by
122
References
3
FWCI
5.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. https://app.cochat.ai/papers/10.1215/15228517-2007-006
The paper
Kesari, S., Schiff, D., Doherty, L., Gigas, D. C., Batchelor, T. T., Muzikansky, A., O'Neill, A., Drappatz, J., Chen-Plotkin, A. S., Ramakrishna, N., Weiss, S. E., Levy, B., Bradshaw, J., Kracher, J., Laforme, A., Black, P. M., Folkman, J., Kieran, M., & Wen, P. Y. (2007). Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-Oncology. https://doi.org/10.1215/15228517-2007-006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.